HUT74732A - Use of xanthine derivatives for reducing the pathological hyper-reactivity of eosinophilic granulocytes, novel xanthine compounds and process for producing them - Google Patents

Use of xanthine derivatives for reducing the pathological hyper-reactivity of eosinophilic granulocytes, novel xanthine compounds and process for producing them Download PDF

Info

Publication number
HUT74732A
HUT74732A HU9602712A HU9602712A HUT74732A HU T74732 A HUT74732 A HU T74732A HU 9602712 A HU9602712 A HU 9602712A HU 9602712 A HU9602712 A HU 9602712A HU T74732 A HUT74732 A HU T74732A
Authority
HU
Hungary
Prior art keywords
formula
compound
methyl
xanthine
ethyl
Prior art date
Application number
HU9602712A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9602712D0 (en
Inventor
Hiristo Anagnostopulos
Ulrich Gebert
Alexander Kapp
Claus Kroegel
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of HU9602712D0 publication Critical patent/HU9602712D0/hu
Publication of HUT74732A publication Critical patent/HUT74732A/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU9602712A 1994-04-05 1995-03-21 Use of xanthine derivatives for reducing the pathological hyper-reactivity of eosinophilic granulocytes, novel xanthine compounds and process for producing them HUT74732A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4411660A DE4411660A1 (de) 1994-04-05 1994-04-05 Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung

Publications (2)

Publication Number Publication Date
HU9602712D0 HU9602712D0 (en) 1996-11-28
HUT74732A true HUT74732A (en) 1997-02-28

Family

ID=6514636

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9602712A HUT74732A (en) 1994-04-05 1995-03-21 Use of xanthine derivatives for reducing the pathological hyper-reactivity of eosinophilic granulocytes, novel xanthine compounds and process for producing them

Country Status (11)

Country Link
EP (1) EP0758239A1 (de)
JP (1) JPH09510983A (de)
KR (1) KR100373948B1 (de)
CN (1) CN1098686C (de)
AU (1) AU695488B2 (de)
CA (1) CA2187081A1 (de)
DE (1) DE4411660A1 (de)
HU (1) HUT74732A (de)
RU (1) RU2159617C2 (de)
UA (1) UA39136C2 (de)
WO (1) WO1995026727A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US5985592A (en) * 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
WO1999049865A1 (en) * 1998-03-31 1999-10-07 Mayo Foundation For Medical Education And Research Use of platelet activating factor (paf) inhibitors to inhibit il-5 induced eosinophil activation or degranulation
EP1719772A1 (de) * 2002-05-31 2006-11-08 Schering Corporation Verfahren zur Herstellung von Xanthin Phosphodiesterase v Inhibitoren und deren Vorstufen
JP2005529934A (ja) * 2002-05-31 2005-10-06 シェーリング　コーポレイション キサンチンホスホジエステラーゼｖインヒビターおよびその前駆物質を調製するプロセス

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918297D0 (en) * 1989-08-10 1989-09-20 Beecham Group Plc Novel treatment
DD298051A5 (de) * 1989-08-16 1992-02-06 ��@���������@�������k�� Verfahren zur herstellung eines therapeutischen agens zur behandlung von verdauungskrankheiten
GB9023783D0 (en) * 1990-11-01 1990-12-12 Celltech Ltd Pharmaceutical product
IL100195A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament having immuno suppressing activity
WO1993003728A1 (en) * 1991-08-27 1993-03-04 Temple University Of The Commonwealth System Of Xanthine suppression of antigen activation of t- or b-cells
IL99368A (en) * 1991-09-02 1996-01-19 Teva Pharma Preparations for the treatment of psoriasis and atopic dermatitis, which contain the result of xanthine
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds

Also Published As

Publication number Publication date
AU695488B2 (en) 1998-08-13
WO1995026727A1 (de) 1995-10-12
HU9602712D0 (en) 1996-11-28
KR970702044A (ko) 1997-05-13
CA2187081A1 (en) 1995-10-12
CN1145029A (zh) 1997-03-12
UA39136C2 (uk) 2001-06-15
EP0758239A1 (de) 1997-02-19
RU2159617C2 (ru) 2000-11-27
CN1098686C (zh) 2003-01-15
JPH09510983A (ja) 1997-11-04
KR100373948B1 (ko) 2003-06-09
DE4411660A1 (de) 1995-10-12
AU1951095A (en) 1995-10-23

Similar Documents

Publication Publication Date Title
KR100516382B1 (ko) 퀴놀린 유도체
EP0274821B1 (de) Benzopyran-Verbindungen, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
FI89921B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara tertiaera hydroxialkylxantiner
CA2091172C (en) Antiviral compounds and antihypertensive compounds
HU180219B (en) Process for producing substituted xantine derivatives and salts
KR20010071491A (ko) 퀴놀린 유도체
CA2002834C (en) Cycloalkyl xanthines
US5250547A (en) Benzopyran derivatives
HU211741A9 (en) Heterocyclic derivatives
JPH0475911B2 (de)
US4970301A (en) 2-(piperazinyl)-2-oxoethylene-substituted flavonoid compounds
HU193409B (en) Process for producing 2-square bracket -n-cyclohexyl-4-bracket-oxo-1,2,3,5-tetrahydro-imidazo-square bracket-2,1-b-square bracket closed-quinazolin-7-yl-bracket closed-oxy-alkqne-carboxamidyl-square bracket closed-alkan-acides
HUT74732A (en) Use of xanthine derivatives for reducing the pathological hyper-reactivity of eosinophilic granulocytes, novel xanthine compounds and process for producing them
JPH0536436B2 (de)
EP0260127A2 (de) Xanthinderivate, ihre Herstellung und sie enthaltende pharmazeutische Präparate
US20020010333A1 (en) Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation
AU716992B2 (en) Hydroquinone derivative and pharmaceutical use thereof
US4797498A (en) Flavonoxypropanolamines and esters of flavonoxypropanolamines as antiarrhythmic agents
JPH08508242A (ja) オレフィン−置換長鎖化合物
US4798832A (en) Pyrido[1,2-a]pyrimidine compounds, corresponding intermediates and use as SRS-A antagonists
US4438116A (en) Quinoxalinyloxy-amino-propanol compounds with blood pressure lowering and β-blocking properties, their use and pharmaceutical compositions containing them
JPH0524889B2 (de)
JPH06102660B2 (ja) 新規なモルホリン誘導体およびこれらの誘導体を含有する医薬組成物
JPH083165A (ja) ピリドピリミジン誘導体
JPS60161980A (ja) １，３−ジチオ−ル−２−イリデン誘導体